Introduction. Quantitative hepatitis B surface antigen (qHBsAg) combined with HBV DNA
may be useful for predicting chronic hepatitis B (CHB) activity and nucleoside analogue (NA) …

Background We compared rates of hepatitis B surface antigen (HBsAg) loss and
hepatocellular carcinoma (HCC) development in hepatitis B e antigen (HBeAg)-negative …

Abstract Background and Aim Hepatitis B surface antigen (HBsAg) kinetics during long‐term
entecavir therapy has not been well investigated. Methods We described the cumulative …

Methods CHB patients who started entecavir as an initial antiviral therapy were enrolled in
this study. Serum hepatitis B virus (HBV) DNA, HBsAg, and alanine aminotransferase levels …

Methods We administered 0.5 mg of entecavir once daily for more than 12 months to 114
naive chronic hepatitis B (CHB) patients. We measured the levels of liver enzymes …

Cessation of nucleos (t) ide analogue (Nuc) therapy in HBeAg‐negative patients may
increase HBsAg loss rate in patients with sustained remission (SR) and non‐retreated …

Background Treatment cessation in chronic HBV infection may be durable in certain patient
subgroups before hepatitis B surface antigen (HBsAg) seroclearance. The role of serum …

BACKGROUND Characteristics of alterations of serum hepatitis B virus (HBV) RNA in
different chronic hepatitis B (CHB) patients still cannot be fully explained. Whether HBV RNA …

Entecavir (ETV) is reported to result in suppression of hepatitis B virus DNA (HBV DNA)
replication with minimal drug resistance. However, information on the long‐term effect of …

The aim is to explore the clinical values of quantitative detection of serum hepatitis B surface
antigen (HBsAg) and hepatitis B virus e antigen (HBeAg) levels for the virological response …